Table 1. Clinical, imaging and pathology features of the patients included in this pilot phase of the MUTAS trial.
| Features | Measure or category | Value |
|---|---|---|
| Clinical features (n=25) | ||
| Age (years) | Mean (SD) | 55.6 (11.85) |
| Range | 37–81 | |
| Menopausal status | Premenopausal | 15 |
| Menopausal | 10 | |
| Palpable lymph nodes | Yes | 14 |
| No | 11 | |
| cT | cT1 | 13 |
| cT2 | 12 | |
| cN | cN1 | 25 |
| Imaging features | ||
| Breast cancer focality (n=25) | Unifocal | 24 |
| Multifocal | 1 | |
| Number of suspicious nodes on US (n=25) | 1 | 13 |
| 2 | 8 | |
| 3 | 4 | |
| Number of suspicious nodes on CT (n=25) | 0 | 10 |
| 1 | 9 | |
| 2 | 6 | |
| Number of suspicious nodes on MRI (n=20) | 0 | 2 |
| 1 | 9 | |
| 2 | 9 | |
| Axillary node positivity confirmation (n=25) | Cytology | 18 |
| Biopsy | 7 | |
| Surgical specimen features (n=25) | ||
| Tumor pathology size (mm) | Median (range) | 22.55 (3.1–130.0) |
| Pathology type | Invasive carcinoma NST | 18 |
| Lobular invasive carcinoma | 7 | |
| ER (%) | Mean (SD) | 92.24 (14.22) |
| Range | 30–99 | |
| PR (%) | Mean (SD) | 64.00 (38.11) |
| Range | 0–99 | |
| Ki67 index (%) | Mean (SD) | 20.80 (13.12) |
| Range | 5–60 | |
| C-erbB2/HER2 status | Negative | 25 |
| Histological grade | I | 4 |
| II | 16 | |
| III | 5 | |
| Tumor necrosis | No | 23 |
| Yes | 2 | |
| Tumor lymphatic invasion | No | 12 |
| Yes | 13 | |
| Number of excised ALN (overall)* | Median [range] | 15 [9–25] |
| Number of infiltrated ALN (overall)* | Median [range] | 3 [1–8] |
| pT | pT1 | 15 |
| pT2 | 7 | |
| pT3 | 2 | |
| pT4b | 1 | |
| pN | pN1 | 17 |
| pN2 | 8 | |
*, includes the marked infiltrated node, the SNs, and the remaining axillary lymph nodes. MUTAS, Multimodal Targeted Axillary Surgery; SD, standard deviation; US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; ER, estrogen receptor; PR, progesterone receptor; ALN, axillary lymph node; SN, sentinel node.